Last reviewed · How we verify

NCT06673472

Comparison of Long-term Outcomes Between Upfront Surgery and Neoadjuvant Therapy Followed by Surgery in Patients with Node-Negative Gastric Cancer

Completed Last updated 5 November 2024
What this trial tests

trial in Lymph Node-negative in 1,081 participants. Completed in 15 September 2024.

Timeline
1 May 2024
Primary endpoint
4 September 2024
15 September 2024

Quick facts

Lead sponsorChang-Ming Huang, Prof.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,081
Start date1 May 2024
Primary completion4 September 2024
Estimated completion15 September 2024
Sites1 location across China

Conditions studied

Sponsor

Chang-Ming Huang, Prof. — full company profile →

Who can join

Adults 18 to 80, any sex, with Lymph Node-negative or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with lymph node-negative gastric cancer, the prognosis of patients who underwent neoadjuvant therapy was poor than that of those who had upfront surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Chang-Ming Huang, Prof. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06673472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing